Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

August 10, 2023

Study Completion Date

March 31, 2026

Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
BIOLOGICAL

Benralizumab

30 mg/mL solution for injection in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC)

BIOLOGICAL

Mepolizumab

3x100 mg vials of powder for solution for injection reconstituted into 3 separate 1 mL syringes for administration on each dosing occasion. Injection volume per syringe is 1 mL. Mepolizumab active solution will be administered subcutaneously (SC)

BIOLOGICAL

Placebo to Mepolizumab

Matching placebo: 0.9% sodium chloride, solutions for injection in 1mL syringes (3 syringes will be used on each dosing occasion). Injection volume per syringe is 1mL. Placebo to Mepolizumban will be administered subcutaneously (SC)

BIOLOGICAL

Placebo to Benralizumab

Matching placebo solution for injection in APFS, 1 mL fill volume. Placebo solution will be administered subcutaneously (SC)

Trial Locations (50)

1070

Research Site, Brussels

1090

Research Site, Brussels

10021

Research Site, New York

10128

Research Site, Torino

11021

Research Site, Great Neck

12100

Research Site, Cuneo

13915

Research Site, Marseille

19104

Research Site, Philadelphia

20132

Research Site, Milan

20162

Research Site, Milan

20251

Research Site, Hamburg

21079

Research Site, Dijon

23538

Research Site, Lübeck

31059

Research Site, Toulouse

34090

Research Site, Montpellier

44093

Research Site, Nantes

48109

Research Site, Ann Arbor

50141

Research Site, Florence

52621

Research Site, Ramat Gan

73230

Research Site, Kirchheim

75014

Research Site, Paris

75020

Research Site, Denison

75877

Research Site, Paris

79106

Research Site, Freiburg im Breisgau

80131

Research Site, Napoli

80206

Research Site, Denver

84101

Research Site, Beersheba

87106

Research Site, Albuquerque

91120

Research Site, Jerusalem

92151

Research Site, Suresnes

96049

Research Site, Bamberg

98115

Research Site, Seattle

6423906

Research Site, Tel Aviv

7661041

Research Site, Rehovot

7830604

Research Site, Ashkelon

55905-0001

Research Site, Rochester

T2N 4Z6

Research Site, Calgary

L8N 4A6

Research Site, Hamilton

M5G 1E2

Research Site, Toronto

M5T 3A9

Research Site, Toronto

00168

Research Site, Roma

260-0877

Research Site, Chiba

761-0793

Research Site, Kita-gun

228-0815

Research Site, Sagamihara-shi

980-8574

Research Site, Sendai

162-8666

Research Site, Shinjuku-ku

CB2 0QQ

Research Site, Cambridge

LE3 9QP

Research Site, Leicester

SE19RT

Research Site, London

PO6 3LY

Research Site, Portsmouth

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY